Navigation Links
TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
Date:6/25/2008

TorreyPines Therapeutics' CEO Neil Kurtz, M.D., to Moderate Discussion Following Presentations by Tony Yaksh, Ph.D.; Jerome Goldstein, M.D.; and

Alan J. Tuchman, M.D.

LA JOLLA, Calif., June 25 /PRNewswire/ -- A Webinar hosted by TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) at 11 a.m. EDT on June 25 will bring together industry experts to discuss the opportunity of treating chronic pain, migraine and muscle spasticity through the inhibition of the neurotransmitter glutamate.

The company's President and Chief Executive Officer, Neil Kurtz, M.D., will moderate a discussion following brief presentations by:

-- Tony Yaksh, Ph.D., Professor and Vice Chairman for Research, Department of Anesthesiology, and Professor of Pharmacology at the University of California, San Diego

Dr. Yaksh will present information about glutamate receptors in the

central nervous system as a target for chronic pain therapy. The focus

of his research is the physiology and pharmacology of pain processing.

A member of numerous professional societies, Dr. Yaksh has been a

consultant to the U.S. Food and Drug Administration and serves on the

editorial boards of several journals. He has received many awards,

including the FWL Kerr Award from the American Pain Society and the

American Society of Anesthesiology Award for Excellence in Research.

-- Jerome Goldstein, M.D., Director of the San Francisco Headache Clinic and a board-certified neurologist who focuses on the diagnosis, treatment, prevention and cure of headache

Dr. Goldstein will present information about glutamate receptors in

the brain as a target for acute and prophylactic migraine therapy. He

is a member of the American Headache Society, The International

Headache Society and The National Headache Foundation. Dr. Goldstein

is a Board Certified Neurologist, a Fellow of the American Academy of

Neurology, and has special qualification for the treatment of headache

from the National Headache Foundation. He has received many industry

awards, published articles in industry journals and served on advisory

boards related to the development of a wide range of headache

therapies.

-- Alan J. Tuchman, M.D., Clinical Professor of Neurology and Pharmacology at New York Medical College, Principal of a neuroscience-focused consulting firm and a board-certified neurologist

Dr. Tuchman will present information about glutamate receptors in the

spinal cord as a target for muscle spasticity. He has served as Vice

Chairman of the Department of Neurology at New York Medical College as

well as Vice Dean of Clinical Affairs, which involved the development

and management of clinical care and medical education policy for 29

affiliated hospitals. In addition, he was President of the Epilepsy

Society of Southern New York. Dr. Tuchman is a frequent speaker about

neuroscience topics at academic meetings.

"There's a growing body of scientific and clinical evidence that supports the further development of drugs that block the glutamate cascade," said Dr. Kurtz. "As the American Headache Society prepares to kick off its 50th Annual Scientific Meeting, we want to provide patients as well as the medical community with industry experts' perspectives as to what is clearly a promising approach for the treatment of migraine and other conditions."

TorreyPines Therapeutics' lead compound, tezampanel is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for chronic pain. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord trauma, stroke and multiple sclerosis.

Webinar Information

Participants can access the Webinar by clicking on the link located on the home page of TorreyPines Therapeutics' Web site at http://www.torreypinestherapeutics.com. Individuals interested in asking questions should also participate via telephone by calling 888-823-7457 in the United States or 973-935-8504 outside of the United States and entering conference ID 48658866. Participants are encouraged to log on at least 15 minutes prior to the beginning of the Webinar. A replay of the Webinar will be available on TorreyPines Therapeutics' Web site until July 25.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for tezampanel and NGX426 as treatments for migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord trauma, stroke and multiple sclerosis. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials conducted in the future, will prove successful, and if successful, whether the results can be replicated. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
3. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
4. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
5. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
6. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
7. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ABU DHABI , UAE, May 23, 2016 ... the importance of Precision Medicine and the role ...     The First International ... under the distinguished patronage and presence of Sheikh ... Development. The conference focused in Precision Medicine, which helps provide ...
(Date:5/23/2016)... FRANCISCO , May 23, 2016 ... to reach USD 5.0 billion by 2022, according to ... increasing generation of medical waste coupled with the lack ... industry is expected to drive the demand for reprocessed ... these devices as compared to that of the original ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
Breaking Medicine Technology:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... The Society ... MSW, has decided to move on from that role. , “No one in Washington ... did Phyllis Greenberger,” said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... to residents of Westchester County for over 24 years, recently hosted its sixth ... members joined HOW for two remembrance ceremonies, each concluding with the release of ...
(Date:5/23/2016)... , ... May 23, 2016 , ... VitreosHealth is presenting ... 10, 2016 from 11:00 AM – 12:00 PM ET. To register, click ... start a proactive outreach program built on Big Data with a new predictive and ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... information management systems (LIMS), electronic laboratory notebook systems (ELNS) and related systems is ... manual data management consumes a significant amount of lab technician time and introduces ...
(Date:5/23/2016)... ... May 23, 2016 , ... SPH ... as Chief Medical Officer. Dr. O’Connor’s deep expertise in medicine and HIT will ... services teams who deliver best-in-class solutions and transformative technologies for provider, payer, and ...
Breaking Medicine News(10 mins):